Elevation of-Amyloid 1-42 Autoantibodies in the Blood of Amnestic Patients With Mild Cognitive Impairment

Interventions: The titer of -amyloid 1-42 autoantibodies in the plasma was obtained at the time of diagnosis and evaluated by enzyme-linked immunosorbent assay before and after dissociation of the antigenantibody complexes. A total of 107 patients with MCI were followed up for 36 months; 70 of the 107 cases progressed to Alzheimer disease. Results: The average level of -amyloid 1-42 plasma autoantibodies in patients with MCI that progressed to Alzheimer disease, but not that of the stable cases, was significantly higher than in cognitively normal controls (P .001).

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[2]  H. Fukuyama,et al.  Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease , 2008, Proceedings of the National Academy of Sciences.

[3]  G. Perry,et al.  Antigen–antibody dissociation in Alzheimer disease: a novel approach to diagnosis , 2008, Journal of neurochemistry.

[4]  Dietmar Rudolf Thal,et al.  Cerebral amyloid angiopathy and its relationship to Alzheimer’s disease , 2008, Acta Neuropathologica.

[5]  E. Zamrini,et al.  Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Aβ and RAGE peptides , 2004, Neurobiology of Aging.

[6]  N. Relkin,et al.  Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals , 2002, Experimental Gerontology.

[7]  W. Pardridge,et al.  Expression of the neonatal Fc receptor (FcRn) at the blood–brain barrier , 2002, Journal of neurochemistry.

[8]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[9]  W. Oertel,et al.  Reduced levels of amyloid β-peptide antibody in Alzheimer disease , 2001, Neurology.

[10]  B. Hyman,et al.  Autoantibodies to amyloid‐β and Alzheimer's disease , 2001, Annals of neurology.

[11]  L. Ferrucci,et al.  Formal education as an effect modifier of the relationship between Mini-Mental State Examination score and IADLs disability in the older population , 1997, Aging.

[12]  Hans Förstl,et al.  Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay* , 1996, The Journal of Biological Chemistry.

[13]  D. T. Vernier,et al.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.

[14]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[15]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[16]  C. Caltagirone,et al.  Amyloid-beta42 plasma levels are elevated in amnestic mild cognitive impairment. , 2009, Journal of Alzheimer's disease : JAD.

[17]  B. Hyman,et al.  Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. , 2008, Archives of neurology.

[18]  C. Colton,et al.  Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. , 2008, Journal of Alzheimer's disease : JAD.

[19]  R. Petersen,et al.  Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. , 2007, Archives of neurology.

[20]  A. Hofman,et al.  Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. , 2006, The Lancet. Neurology.

[21]  H. Möller,et al.  Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. , 2004, Molecular psychiatry.

[22]  W. Oertel,et al.  Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. , 2003, Brain : a journal of neurology.

[23]  Charles D. Smith,et al.  Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. , 2003, Neuromolecular medicine.

[24]  E. Tangalos,et al.  CME Practice parameter: , 2022 .

[25]  S. Younkin,et al.  Age-Dependent Changes in Brain , CSF , and Plasma Amyloid b Protein in the Tg 2576 Transgenic Mouse Model of Alzheimer ’ s Disease , 2001 .

[26]  V. Leirer,et al.  Development and validation of a geriatric depression screening scale: a preliminary report. , 1982, Journal of psychiatric research.